News / 

Stocks down...Oil prices drop... Grubhub to buy Eat24

Save Story
Leer en Español

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) — Stocks are mostly lower on Wall Street, but the Dow Jones industrial average of 30 blue-chip stocks still managed to post its eighth gain in a row and close at another record high. The Dow closed up 9 points, less than 0.1 percent, to 22,026. The Standard & Poor's 500 index slipped 5 points, or 0.2 percent, to 2,472. The Nasdaq fell 22 points, or 0.4 percent, to 6,340.

NEW YORK (AP) — Oil prices are lower today. Benchmark U.S. crude dipped 56 cents, or 1.1 percent, to $49.03 a barrel in New York. Meanwhile, Brent crude, the international standard, fell 35 cents to $52.01 a barrel in London.

NEW YORK (AP) — Grubhub plans to gobble up another online food-ordering rival: This time it's Yelp's Eat24. Chicago-based Grubhub is paying Yelp $287.5 million for Eat24. That's more than double what Yelp, based in San Francisco, paid to acquire Eat24 two years ago. The two companies also announced a 5-year deal that will allow readers of Yelp's reviews to order food from restaurants that use Grubhub.

NEW YORK (AP) — Dunkin' is thinking about dumping "Donuts" from its name. A new location of the chain in Pasadena, California, will be simply called Dunkin', a move that parent company Dunkin' Brands calls a test. The Canton, Massachusetts-based company says a few other stores will get the one-name treatment too. The chain wants people to think of its stores as a destination for coffee, not just doughnuts. No final decision will be made until late next year.

UNDATED (AP) — Regulators have approved another drug to treat all forms of hepatitis C that works in as little as eight weeks. AbbVie's drug, Mavyret (mav-EH'-rit), was approved today by the Food and Drug Administration for patients without significant cirrhosis who haven't been treated previously for the liver-destroying virus, plus those with a form of hepatitis who weren't cured by a prior treatment. Hepatitis C affects at least 2.7 million people in the U.S.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent News stories

The Associated Press


    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the Trending 5.
    By subscribing, you acknowledge and agree to's Terms of Use and Privacy Policy.

    KSL Weather Forecast